Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$80.5B
103M shares
52-week range
$541.00 – $859.34
79% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
5.4
EV / FCF (TTM)
23.9
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
www.regeneron.comNo one on the platform currently holds REGN.
| Institution | Shares | Reported |
|---|---|---|
| Scion Asset ManagementCALLas of 2025-06-30 | 200,000 | $105.0M |
| Renaissance Technologiesas of 2026-03-31 | 66,802 | $51.6M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-18 | $0.9400 | 2026-08-31 |
| 2026-05-20 | $0.9400 | 2026-06-04 |
| 2026-02-20 | $0.9400 | 2026-03-05 |
| 2025-11-20 | $0.8800 | 2025-12-05 |
| 2025-08-18 | $0.8800 | 2025-09-03 |
| 2025-05-20 | $0.8800 | 2025-06-06 |
| 2025-02-20 | $0.8800 | 2025-03-20 |
No one on the platform has traded REGN yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.0% | 20.3% | 22.0% | — | — | — |
| Rev. Growth % | 1.0% | 11.0% | ||||
| Profit Margin % | 31.4% | 35.7% | 32.7% | |||
| Free Cash Flow Margin % | 28.4% | 31.8% | 27.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +0.6% on the P/E track.
At today's price, your expected annual return is +8.2% on the P/E track.
At today's price, your expected annual return is +14.4% on the P/E track.
| 22,724 |
| $17.6M |
| Scion Asset Managementas of 2025-06-30 | 15,000 | $7.9M |
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $17.1B | +19.7% | $54.51 | $44.56–$59.87 | 14.5× | 16 |
| 2027 | $18.6B | +9.1% | $61.24 | $47.34–$68.82 | 12.9× | 10 |
| 2028 | $19.9B | +6.8% | $68.43 | $61.06–$78.13 | 11.6× | 8 |
| 2029 | $21.3B | +7.4% | $75.64 | $65.17–$83.18 | 10.5× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $10.16 | $14.29 | +40.6% |
| 2026-04-29 | $8.91 | $9.47 | +6.3% |
| 2026-01-30 | $10.74 | $11.44 | +6.5% |
| 2025-10-28 | $9.65 | $11.83 | +22.6% |
| 2025-08-01 | $8.43 | $12.89 | +52.9% |
| 2025-04-29 | $8.62 | $8.22 | -4.6% |
| 2025-02-04 | $11.21 | $12.07 | +7.7% |
| 2024-10-31 | $11.69 |
| $12.46 |
| +6.6% |
| $63.5B |
| — |
| ELVElevance Health Inc. | $424.24 | +1.32% | $92.0B | — |
| GMABGenmab A/S | $32.65 | +0.55% | $20.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$OTLK $REGN $NVS $ABBV When the #Bollingerbands #squeeze, the #market is about to?
View on StockTwits ↗
#Eyecare #Healthcare #FDAApproved Is the parent #molecule of ranibizumab=bevacizumab? $REGN #congrats for the #win #in2006 during the #presidency of #President #George #Bush, and $OTLK #congrats #forthewin #in2026 during the #presidency of #President #Donald #Trump! #GeorgeBush #DonaldTrump #FDA #Gov #government Do #you think #affordable bevacizumab’s #approval for wet age related macular degeneration is a win for #patients, #doctors, #Medicare, #Medicaid, #USA, #UnitedStates, #seniors, #insurers, #insurance, and #families?
View on StockTwits ↗
$REGN faces a securities class action alleging misleading trial disclosures.
View on StockTwits ↗
$REGN printed a new 52-week high today
View on StockTwits ↗
$OTLK $COR $REGN And the insider buying over the past few weeks deserves attention. 👀 2,772,165 shares bought for roughly $2.75M by GMS Ventures, CEO Robert Jahr and Director Faisal Ghiath Sukhtian. Plus 2,676,767 warrants at $1.10 attached to the GMS/CEO purchases. Insiders were willing to put millions into $OTLK at $0.99–$1.0482 while the stock is now trading around $0.61. Are they stupid… or do they know exactly what they’re buying? 👀
View on StockTwits ↗$OTLK $COR $REGN ~$152M market cap. ~$0.61/share. ~$62M cash. FDA approval secured. A commercial product. Expected 12-year U.S. reference product exclusivity. European commercialization underway. Cencora already in place as a strategic U.S. launch partner. U.S. launch targeted for year-end 2026. $50–75M expected revenue in the first 12 months and a >$500M annual U.S. sales base-case target before 2030. These are the kind of prospects biotech companies dream about BEFORE FDA approval. $OTLK already has the approval, product, cash, market, strategic partner and potentially 12 years of U.S. exclusivity. The valuation simply doesn’t seem to reflect what is already in place. LOL
View on StockTwits ↗
$REGN Only stock long in biotech. I said I will sell at $900-1000 and we’re getting there !!!
View on StockTwits ↗$PPH What’s closest to when you predict there might be anything firm announced related to compounded bevacizumab for wet AMD, given the FDA approval of #OutlookTherapeutic’s ophthalmic bevacizumab won approval for wet AMD 7/24/26? $OTLK $REGN $NVS #eyecare #healthcare
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.